Byetta FDA Approval History
FDA Approved: Yes (First approved April 28, 2005)
Brand name: Byetta
Generic name: exenatide
Dosage form: Injection
Company: Amylin Pharmaceuticals / Eli Lilly & Co.
Treatment for: Diabetes, Type 2
Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Development timeline for Byetta
| Date | Article |
|---|---|
| Oct 20, 2011 | Approval Byetta Approved for Use with Insulin Glargine in the U.S. |
| Nov 2, 2009 | Approval Byetta Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes |
| Apr 28, 2005 | Approval Byetta Amylin Pharmaceuticals / Eli Lilly & Co. - Treatment for Type 2 Diabetes |
| Sep 1, 2004 | Exenatide New Drug Application Accepted for Review by the FDA |
| Jun 30, 2004 | New Drug Application for Exenatide Submitted to FDA for Type 2 Diabetes |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.